Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0699790 (
colon cancer
)
28,837
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Colon cancer
is the third most common cancer worldwide. Many miRNAs have been reported to be involved in
colon cancer
progression. However, there are only a few studies on the role of miR-219a-1 in
colon cancer
, and the molecular mechanisms involved remain unclear. The aim of this study was to investigate the miR-219a-1 level in patients with
colon cancer
and to explore both the effects and regulatory mechanisms of miR-219a-1 in the malignancy of
colon cancer
cells. Real-time PCR and western blot analysis were used to analyze the expression levels of miR-219a-1 and mediator of ErbB2-driven cell motility 1. Cell Counting Kit-8, transwell and wound-healing assays were performed to investigate the malignant ability of
colon cancer
cells. A luciferase assay was performed to explore whether miR-219a-1 could directly bind to 3'-UTR region of
MEMO1
. miR-219a-1 was found to be downregulated in
colon cancer
cell lines and in patients with
colon cancer
. Additionally, miR-219a-1 could inhibit
colon cancer
cell proliferation, invasion and migration. We identified
MEMO1
as a novel potential target gene of miR-219a-1. Luciferase assays showed that miR-219a-1 could directly bind to 3'-UTR of
MEMO1
. Overexpression of miR-219a-1 in
colon cancer
cells could inhibit the expression of
MEMO1
. Furthermore,
MEMO1
was upregulated in patients with
colon cancer
, which was inversely correlated with miR-219a-1 levels. In conclusion, our study revealed that miR-219a-1 exerts anti-tumor effects and regulates
colon cancer
cell proliferation, invasion and migration by targeting
MEMO1
, suggesting that miR-219a-1 could act as a therapeutic target in
colon cancer
.
...
PMID:miR-219a-1 inhibits colon cancer cells proliferation and invasion by targeting
MEMO1
. 3321 85